Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZP-3601 · 1 trial · 1 indication
Number of Treatment Emergent Adverse Events (TEAEs), as assessed by medDRA (v25).
| Arm | Type | Description |
|---|---|---|
| AZP-3601 | EXPERIMENTAL | subcutaneous (sc) administration once daily |
| Placebo (Parts A and B) | PLACEBO_COMPARATOR | subcutaneous (sc) administration once daily |
| Name | Type | Description |
|---|---|---|
| AZP-3601 | DRUG | Lyophilized powder of AZP-3601 to be reconstituted with water for injection before injection |
| Placebo | DRUG | Saline solution visually matching active medication |
Main inclusion criteria * Part A: healthy male volunteers aged 18 to 60 years old inclusive with a body mass index of 19 to 28 kg/m2 * Part B: healthy male and female volunteers (non-child bearing potential) aged 18 to 60 years inclusive with a Body mass index of 19 to 28 kg/m2 * Part C: 1. Male...
AZP-3601 is an investigational small molecule being developed for the treatment of chronic hypoparathyroidism, a condition characterized by low levels of parathyroid hormone. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
AZP-3601 is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 1 clinical trials for chronic hypoparathyroidism.
AZP-3601 is in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval. A Phase 1 trial has been completed, and the drug remains under investigation for chronic hypoparathyroidism.
AZP-3601 has one completed Phase 1 clinical trial, identified as NCT05239221. This study was a single ascending dose and multiple ascending dose trial conducted in healthy subjects and patients with hypoparathyroidism, enrolling 132 participants across Hungary and the Netherlands.
AZP-3601 is the primary name for this investigational drug. No alternative names have been reported for this compound. It is being studied under the clinical trial identifier NCT05239221 for chronic hypoparathyroidism.